Keryx Biopharmaceuticals (KERX) Stock Price, News & Analysis

Company Overview

Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis. The company has strategic alliances with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of ferric citrate in Japan; and with Panion & BF Biotech, Inc. for the development and marketing of ferric citrate. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $2.97 to $3.47
• 50-Day Range: N/A
• 52-Week Range: $2.47 to $5.98
• Volume: 2.60 million shs
• Average Volume: 1.69 million shs
• Market Capitalization: $344.00 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

KERX Stock Analysis - Frequently Asked Questions

How were Keryx Biopharmaceuticals' earnings last quarter?

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) issued its quarterly earnings data on Thursday, November, 8th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.01. The biopharmaceutical company earned $28.04 million during the quarter, compared to the consensus estimate of $29.56 million.

What other stocks do shareholders of Keryx Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Keryx Biopharmaceuticals investors own include Synergy Pharmaceuticals (SGYP), Bristol Myers Squibb (BMY), Amyris (AMRS), Gilead Sciences (GILD), Exelixis (EXEL), Meta Platforms (META) and Immunomedics (IMMU).

Company Calendar

• Last Earnings: 11/08/2018
• Today: 8/06/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:KERX
• CIK: 1114220
• Web: www.keryx.com
• Phone: 617-466-3500
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.88)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$163.44 million
• Net Margins: -96.41%
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -60.05%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.21
• Quick Ratio: 1.19

Sales & Book Value

• Annual Sales: $60.64 million
• Price / Sales: 5.67
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.12) per share
• Price / Book: -28.00

Miscellaneous

• Outstanding Shares: 102,380,000
• Free Float: N/A
• Market Cap: $344.00 million
• Optionable: Optionable
• Beta: 2.35